aciclovir
Lung Transplant
Fernanda P Silveira, MD, MSSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Lung Transplant cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Valganciclovir Fernanda P Silveira, MD, MS | Phase 2 | B |
Letermovir Fernanda P Silveira, MD, MS | Phase 2 | B |
Inomax Mallinckrodt | Phase 2 | CCC |
Sonovue Thunder Bay Regional Health Research Institute | Early Phase 1 | C |
PERFLUTREN Thunder Bay Regional Health Research Institute | Early Phase 1 | C |
Helium Thunder Bay Regional Health Research Institute | Early Phase 1 | C |
XENON Thunder Bay Regional Health Research Institute | Early Phase 1 | C |
Same molecule, other indications
aciclovir is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →